Drugs / Semi-allogenic human fibroblast (MRC-5) transfected with DNA
Semi-allogenic human fibroblast (MRC-5) transfected with DNA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02211027 | Sep 2016 → Oct 2017 | head and neck squamous cell carcinoma | Robert Ferris | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Semi-allogenic human fibroblast (MRC-5) transfected with DNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02211027 ↗ |
| Modality | Vaccine | “receiving the tumor DNA-transfected fibroblast vaccine” NCT02211027 ↗ |